Neko Health raises $700M to bring AI body scans to New York

Neko Health completed a $700 million Series C round led by Lightspeed Venture Partners and co-led by O.G. Venture Partners to expand its AI-powered full-body scan clinics into the United States, beginning with a site in New York. The financing will support clinic openings, research and development, and wider deployment of the company’s proprietary scanning equipment.

Company materials list participation from existing investors Atomico, General Catalyst and Lakestar, and new backers including Liberty City Ventures, Positive Sum and BDT & MSD. David Ofer of O.G. Venture Partners is expected to join Neko’s board pending regulatory approval. The disclosed capital raised since 2023 now exceeds $1 billion after prior rounds of $65 million in 2023 and $260 million in January 2025. Individual investors from earlier rounds include Mark Zuckerberg and Priscilla Chan, Maria Sharapova, will.i.am, Thierry Henry, Alexis Ohanian and Zoë Saldaña.

Neko operates clinic-based preventive screenings that combine full-body imaging, on-site blood tests, proprietary sensors, artificial intelligence and clinician review in a single appointment. The company markets a roughly 60-minute, non-invasive, radiation-free assessment that screens for signs of skin cancer, cardiovascular disease, diabetes and risk factors linked to metabolic syndrome, stroke and heart attack. The package includes an electrocardiogram, arterial measurements, body-composition analysis and more than 2,000 high-resolution skin images. Blood samples are processed on site so many results can be reviewed during the same visit and discussed with a medical professional.

The company currently runs eight clinics in the U.K. and Sweden: four in London, two in Stockholm and sites in Manchester and Birmingham. Neko reports it has completed 100,000 scans since launching in 2023 and that more than 350,000 people have registered for scans or joined waitlists. Company figures indicate about 75% of customers prepay for a follow-up scan at the end of an appointment. A waitlist for the New York clinic is open on Neko’s website; the company has not published U.S. prices or a detailed rollout schedule.

Neko recently updated its Derma, Echo and Spectrum devices, and added body-composition measurements and clinician review of wearable-device data across clinics. Two internally developed devices received U.S. Food and Drug Administration 510(k) clearance in May 2026: Derma-2 was cleared as an adjunctive telethermographic system and Spectrum-2 as a tissue-saturation oximeter for cardiovascular measurements. The FDA clearances apply to those specific devices and their intended uses, not to the complete Neko Health Scan as a single FDA-approved screening service.

Neko describes its U.S. clinics as preventive health and wellness providers and instructs customers to continue seeing their usual clinicians for diagnoses and treatment. Specialist clinicians, including dermatologists and cardiologists, review findings that require further assessment; when recommended, the company arranges follow-up appointments, referral letters and introductions to outside specialists.

The company’s U.S. clinics do not currently participate in health insurance plans and most services are expected to be paid for directly by customers. Neko has not disclosed whether employers, insurers or other organisations might subsidize access or the expected costs of diagnostic tests and treatments arranged outside the company.

Public materials reviewed do not include a completed peer-reviewed study validating the full multimodal screening service. A trial registered on ClinicalTrials.gov is evaluating Neko’s multimodal skin-imaging technology and remains ongoing. Neko reported outcome data from 1,469 customers who returned for a second scan about one year after their first and noted improvements in blood pressure, cholesterol and blood sugar, while acknowledging the analysis was not a scientific study, lacked a control group and did not establish causation.

The company was founded in 2018 by Spotify co-founder Daniel Ek and CEO Hjalmar Nilsonne. Neko stated part of the new capital will fund further research and development. The company did not disclose a post-money valuation; unnamed sources have estimated it at about $7 billion.